Hospital outcomes in patients presenting with congestive heart failure complicating acute myocardial infarction: A report from the Second National Registry of Myocardial Infarction (NRMI-2)

Journal of the American College of Cardiology

Volumn 40, Issue 8, 2002, Pages 1389-1394

  Wu, Audrey H ^a   Parsons, Lori ^b   Every, Nathan R ^a   Bates, Eric R ^c,d  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Ovation Research Group   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOLYTIC AGENT; HEPARIN;

ACUTE HEART INFARCTION; ADULT; AGE DISTRIBUTION; AGED; ANGIOPLASTY; ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE COURSE; FEMALE; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; SEX DIFFERENCE; SEX RATIO; ST SEGMENT ELEVATION;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; FEMALE; HEART FAILURE, CONGESTIVE; HOSPITAL MORTALITY; HUMANS; LENGTH OF STAY; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; PHYSICIAN'S PRACTICE PATTERNS; PROGNOSIS; REGISTRIES; THROMBOLYTIC THERAPY;

EID: 0037120938     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(02)02173-3     Document Type: Article

References (43)

1. Bates ER, Moscucci M. Post-infarction cardiogenic shock. In: Brown DL, editor. Cardiac Intensive Care. Philadelphia, PA: W.B. Saunders, 1998, 215-27.
2. Hochman JS, Sleeper LA, Webb JG, et al., for the SHOCK Investigators. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. N Engl J Med 1999;341:625-34.
3. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986;1:397-402.
4. Gruppo Italiano per lo Studio della Sopravivenza nell'Infarto Miocardico. GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 1990;336:65-71.
5. The International Study Group. In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. Lancet 1990;336:71-5.
6. Rott D, Behar S, Gottlieb S, Boyko V, Hod H. Usefulness of the Killip classification for early risk stratification of patients with acute myocardial infarction in the 1990s compared with those treated in the 1980s. Am J Cardiol 1997;80:859-64.
7. Miller WL, Wright RS, Grill JP, Kopecky SL. Improved survival after acute myocardial infarction in patients with advanced Killip class. Clin Cardiol 2000;23:751-8.
8. Emanuelsson H, Karlson BW, Herlitz J. Characteristics and prognosis of patients with acute myocardial infarction in relation to occurrence of congestive heart failure. Eur Heart J 1994;15:761-8.
9. Spencer FA, Meyer TE, Goldberg RJ, et al. Twenty year trends (1975-1995) in the incidence, in-hospital and long-term death rates associated with heart failure complicating acute myocardial infarction: a community-wide perspective. J Am Coll Cardiol 1999;34:1378-87.
10. Ali AS, Rybicki BA, Alam M, et al. Clinical predictors of heart failure in patients with first acute myocardial infarction. Am Heart J 1999;138:1133-99.
11. O'Connor CM, Hathaway WR, Bates ER, et al. Clinical characteristics and long-term outcome of patients in whom congestive heart failure develops after thrombolytic therapy for acute myocardial infarction: development of a predictive model. Am Heart J 1997;133:663-73.
12. Gilon D, Leitersdorf I, Gotsman MS, Zahger D, Sapoznikov D, Weiss AT. Reduction of congestive heart failure symptoms by very early fibrinolytic therapy in acute myocardial infarction: a long-term follow-up. Am Heart J 2000;139:1096-1100.
13. Killip T, Kimball JT. Treatment of myocardial infarction in a coronary care unit: a two year experience with 250 patients. Am J Cardiol 1967;20:457-64.
14. Fresco C, Carinci F, Maggioni AP, et al. Very early assessment of risk for in-hospital death among 11,483 patients with acute myocardial infarction. Am Heart J 1999;138:1058-64.
15. Lee KL, Woodlief LH, Topol EJ, et al., for the GUSTO-I Investigators. Predictors of 30-day mortality in the era of reperfusion for acute mvocardial infarction: results from an international trial of 41,021 patients. Circulation 1995;91:1659-68.
16. Morrow DA, Antman EM, Parsons L, et al. Application of the TIMI risk score for ST-elevation MI in the National Registry of Myocardial Infarction 3. JAMA 2001;286:1356-9.
17. Rogers WJ, Bowlby LJ, Chandra NC, et al. Treatment of myocardial infarction in the United States (1990 to 1993): observations from the National Registry of Myocardial Infarction. Circulation 1994;90:2103-14.
18. The GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet 2001;357:1905-14.
19. The ASSENT-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001;358:605-13.
20. Stone PH, Raabe DS, Jaffe AS, et al., for the MILIS Group. Prognostic significance of location and type of myocardial infarction: independent adverse outcome associated with anterior location. J Am Coll Cardiol 1988;11:453-63.
21. Crimm A, Severance HW, Coffey K, McKinnis R, Wagner GS, Califf RM. Prognostic significance of isolated sinus tachycardia during first three days of acute myocardial infarction. Am J Med 1984;76:983-8.
22. Canto JG, Shlipak MG, Rogers WJ, et al. Prevalence, clinical characteristics, and mortality among patients with myocardial infarction presenting without chest pain. JAMA 2000;283:3223-9.
23. Werns SW, Bates ER. The enduring value of Killip classification. Am Heart J 1999;137:213-5.
24. Second International Study of Infarct Survival (ISIS-2) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction. Lancet 1988;2:349-60.
25. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985;27:335-71.
26. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-8.
27. Flather MD, Yusuf S, Kober L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet 2000;355:1575-81.
28. Ryan TJ, Anderson JL, Antman EM, et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 1996;28:1328-428.
29. Pashos CL, Normand SL, Garfinkle JB, Newhouse JP, Epstein AM, McNeil BJ. Trends in the use of drug therapies in patients with acute myocardial infarction: 1988 to 1992. J Am Coll Cardiol 1994;23:1023-30.
30. Ellerbeck EF, Jencks SF, Radford MJ, et al. Quality of care for Medicare patients with acute myocardial infarction: a four state pilot study from the Cooperative Cardiovascular Project. JAMA 1995;273:1509-14.
31. Pilote L, Califf RM, Sapp S, et al. Regional variation across the United States in the management of acute myocardial infarction. N Engl J Med 1995;333:565-72.
32. McGovern PG, Pankow JS, Shahar E, et al. Recent trends in acute coronarv heart disease: mortality, morbidity, medical care, and risk factors. N Engl J Med 1996;334:884-90.
33. Viskin S, Kitzis I, Lev E, et al. Treatment with beta-adrenergic blocking agents after myocardial infarction: from randomized trials to clinical practice. J Am Coll Cardiol 1995;25:1327-32.
34. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998;339:489-97.
35. Beta-blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. II. Morbidity results. JAMA 1983;250:2814-9.
36. Chadda K, Goldstein S, Byington R, Curb JD. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation 1986;73:503-10.
37. Lichstein E, Hager WD, Gregory JJ, Fleiss JL, Rolnitzky LM, Bigger JT, for the Multicenter Diltiazem Post-Infarction Research Group. Relation between beta-adrenergic blocker use, various correlates of left ventricular function and the chance of developing congestive heart failure. J Am Coll Cardiol 1990;16:1327-32.
38. The CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001;357:1385-90.
39. Simoons ML, Vos J, Tijssen JGP, et al. Long-term benefit of early fibrinolytic therapy in patients with acute myocardial infarction: 5-year follow-up of a trial conducted by Interuniversity Cardiology Institute of the Netherlands. J Am Coll Cardiol 1989;14:1609-15.
40. Bates ER, Topol EJ. Limitations of thrombolytic therapy for acute myocardial infarction complicated by congestive heart failure and cardiogenic shock. J Am Coll Cardiol 1991;18:1077-84.
41. Rott D, Behar S, Leor J, et al., for the Working Group on Intensive Cardiac Care, Israel Heart Society. Effect on survival of acute myocardial infarction in Killip Classes II or III patients undergoing invasive coronary procedures. Am J Cardiol 2001;88:618-23.
42. DeGeare VS, Boura JA, Grines LL, O'Neill WW, Grines CL. Predictive value of the Killip classification in patients undergoing primary percutaneous coronarv intervention for acute myocardial infarction. Am J Cardiol 2001;87:1035-8.
43. Every NR, Frederick PD, Robinson M, Sugarman J, Bowlby L, Barron HV. A comparison of the National Registry of Myocardial Infarction 2 with the Cooperative Cardiovascular Project. J Am Coll Cardiol 1999;33:1886-94.